Naslov
INFLUENCE OF OVARIAN FUNCTION SUPRESSION ON QUALITY OF LIFE IN BREAST CANCER SURVIVORS ON ADJUVANT ENDOCRINE THERAPY

Autori
Dugonjić Okroša, A. ; Silovski, T. ; Dedić Plavetić, N. ; Jović Zlatović J. ; Jajac Bručić, L. ; Skelin, M. ; Mucalo, I.

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Skup
ASCO 2023 AMERICAN SOCIETY OF CLINICAL ONCOLOGY

Mjesto i datum
Chicago (IL), Sjedinjene Američke Države, 02.06.2023. - 06.06.2023

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
endocrine therapy, breast cancer

Sažetak
Background: Adding ovarian function suppression to adjuvant endocrine therapy (AET) lowers thedisease recurrence rates among premenopausal women with hormone receptor-positive (HR+) earlybreast cancer (BC). However, a detrimental effect on endocrine symptoms burden (ESB) is expected.Therefore, this study aimed to investigate differences inQuality of life(QoL)and endocrinesymptoms inpremenopausalwomen prescribed AET, with and without gonadotropin-releasinghormone agonist (GnRH).Methods: This cross-sectional study included women with early HR+ BC treated with AET for morethan 3 months with and without GnRH. The research was conducted at the University Hospital CentreZagreb, General Hospital Šibenik and online through collaboration with Croatian BC patientassociations. A validated instrument, the Functional Assessment of Cancer Therapy- EndocrineSymptoms (FACT-ES), was used. The collected data were analysed using SPSS v. 29, (p≤0.05).Results: Overall, 314eligible BC survivors with amedian age of 45 years (22-65) and a medianduration of AET of 2 years (3 months–12 years) responded to FACT-ES and were included in theanalysis. Altogether45.2% (n=142) of participants were prescribedtamoxifen (TAM), 25.8% (n=81)GnRH+TAM, and 29%(n=91)GnRH+aromatase inhibitor(AI) ; exemestane (9%), letrozole (13.6%) andanastrozole (6.4%). The total QoL(FACT-ES)score was higher in patientstreated withTAMasopposed topatients treated with AI+GnRH (p=0.01)(Table 1).Adding GnRH to TAM did notsignificantly change QoL when compared to TAM aloneorAI+GnRH.In addition, patients on AI+GnRHhad lowerphysical well-being (PWB)score thanpatientsonTAM+GnRH (p=0.03) orTAMalone(p=0.05) and lower endocrine subscale score (ESS-19) thanpatientsprescribedTAM(p=0.01), indicating more endocrine symptomsin premenopausal women treated withAI+GnRH.Amongpatients treated with AI+GnRH letrozole had lower PWB(p=0.03)and ESS-19 score(p=0.01)thanexemestane. Conclusion:This study showed thatGnRH+AIin premenopausal women with early HR+ BC resultsingreaterESBand lowerQoLcompared to patients treated with TAM or GnRH+TAM. Therefore, interventions helping decrease the ESB in patients treated with AI+GnRH should be explored anddeveloped to help patients adhere to and persist in AET.

Izvorni jezik
Engleski

Znanstvena područja
Farmacija

POVEZANOST RADA